Get started
Author

Yuanjing Hu

Observed name: Yuan-jing Hu
Observed institutions: Nankai University, Tianjin Medical University General Hospital, Nanjing Drum Tower Hospital, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin Medical University, Nanjing University
ORCID: 0009-0000-7286-6792
Observed ORCIDs: 0009-0000-7286-6792, 0000-0002-4631-4115, 0000-0002-4540-7918
OpenAlex ID: A5014331153
PDIA4 confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma
2023 · Lichun Kang, Dekun Wang, et al. · Cell Death and Disease · 84
PDF
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
2022 · Ning Li, Youzhong Zhang, et al. · Journal of Clinical Oncology · 83
Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis
2021 · Yan Zhuang, Hailong Wang, et al. · BMC Cancer · 62
PDF
ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse: A meta-analysis of related studies in Chinese population
2019 · Na Li, Ya He, et al. · Medicine · 31
The High Expression of RRM2 Can Predict the Malignant Transformation of Endometriosis
2021 · Binkai Yang, Tian Wang, et al. · Advances in Therapy · 21
PDF
Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma
2021 · Pu Li, Yuezong Bai, et al. · Frontiers in Oncology · 19
PDF
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
2021 · Hong Zheng, Yunong Gao, et al. · Molecular Cancer Therapeutics · 17
Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population
2021 · Peisong Sun, Yan Shen, et al. · Cancer Epidemiology · 17
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
2025 · Lingfang Xia, Keqiang Zhang, et al. · Journal of Clinical Oncology · 16
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
2025 · Lingying Wu, Jing Wang, et al. · CA A Cancer Journal for Clinicians · 15
PDF
Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma.
2018 · Ling Chen, Xinxin Liu, et al. · Europe PMC (PubMed Central) · 12
Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer
2024 · Wendi Guo, Runling Ren, et al. · European Journal of Surgical Oncology · 10
PDF
RETRACTED ARTICLE: Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway
2022 · Peng Wang, Yuanjing Hu, et al. · Bioengineered · 10
PDF
HNRNPCL1, PRAMEF1, CFAP74, and DFFB: Common Potential Biomarkers for Sporadic and Suspected Lynch Syndrome Endometrial Cancer
2020 · Yuan Gao, Xiuping Zhang, et al. · Cancer Management and Research · 9
PDF
Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer
2021 · Wenwen Wang, Wenwen Zhang, et al. · PeerJ · 7
Molecular mechanisms and differences in lynch syndrome developing into colorectal cancer and endometrial cancer based on gene expression, methylation, and mutation analysis
2022 · Hongfeng Li, Liwei Sun, et al. · Cancer Causes & Control · 6
PDF
Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
2021 · Ning Li, Youzhong Zhang, et al. · Gynecologic Oncology · 6
Prognosis and adjuvant chemotherapy for patients with malignant peritoneal cytology in early-stage non-endometrioid endometrial cancer
2023 · Xinyue Tang, Na Li, et al. · European Journal of Surgical Oncology · 5
Multigene mutation signatures in colorectal cancer patients: Predict for the diagnosis, pathological classification, staging and prognosis.
2020 · Yan Zhuang, Hailong Wang, et al. · Journal of Clinical Oncology · 5
Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent–a cohort study
2025 · Na Li, Pinting Xu, et al. · BMC Women s Health · 4
PDF
The role of TCGA molecular classification in clear cell endometrial carcinoma
2023 · Xinyue Tang, Yuanjing Hu · Frontiers in Oncology · 4
PDF
Effect of collagen scaffold vs. intrauterine device on preventing recurrence of intrauterine adhesions: a multicenter randomized controlled trial
2025 · Huiyan Wang, Xiaoyan Gu, et al. · Fertility and Sterility · 3
Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer
2024 · Xiaohua Wu, Lingfang Xia, et al. · Gynecologic Oncology · 3
Corrigendum to “Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer” [Eur J Surg Oncol. 50 (2024) (11) 108522]
2025 · Wendi Guo, Runling Ren, et al. · European Journal of Surgical Oncology · 1
Construction of dysregulated long non-coding RNA-associated competing endogenous RNA network in uterine corpus endometrial carcinoma
2020 · Na Li, Peng Mi, et al. · Translational Cancer Research · 1
Works count: 31
Citation count: 451
H-index: 11
I10-index: 13
Year
Topic
Type